Search

Keywords: alopecia areata; COVID-19; herpes zoster; vaccine EN alopecia areata COVID-19 herpes zoster vaccine 36 38 3 01/23/23 20230101 NES 230101 The Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic spread over the world in 2019. Herpes zoster and alopecia areata following mRNA BNT162b2 COVID-19 vaccine: Controversial immune effects 2022; 35 (5): e15411. doi: 10.1111/dth.15411 7 May Lee M, Bertolani M, Pierobon E, Lotti T, Feliciani C, Satolli F. Alopecia areata following COVID-19 vaccination: vaccine-induced autoimmunity?. [Extracted from the article]

The author wrote some comments on our recently published article entitled 'Could wide tattoo delay the early diagnosis of cutaneous melanoma? '.[1] The patient described in our paper, skin photo-type III according to Fitzpatrick, had a negative anamnesis for melanoma and a negative family history as well. We agree with the author when he states that the upper back is an area of difficult self-control regardless of the tattoo particularly in unmarried patients,[2] but in our case, the patient's marital status could not affect it since the patient is married. [Extracted from the article]

MM prognosis is related to Breslow index (a measure of deepness of melanoma) and sentinel lymph node. Dear Editor, Herein, we report a case of a 32-year-old woman, Caucasian, phototype IV, with an insurgence of a single pigmented lesion developed on a wide tattoo in the back. [Extracted from the article]

Introduction: Vitiligo is an acquired skin disorder clinically characterized by hypopigmentated macules and patches. Psoriasis is a chronic‐inflammatory‐skin‐condition characterized by erythematous‐plaques covered with scales particularly over the extensor‐surfaces, scalp, and lumbosacral region. Recent major‐researches‐advancements have significantly expanded our understanding of psoriasis‐pathophysiology, resulting in the development of highly effective targeted‐therapies, such as anti TNFα, IL‐12/23‐inhibitors, IL‐17‐inhibitors, or IL‐23‐inhibitors. Particularly, ixekizumab, a humanized‐monoclonal immunoglobulin‐G 4 antibody, specifically binding IL‐17A, demonstrated strong efficacy in threating recalcitrant psoriasis. Nevertheless, paradoxical reactions due to IL‐17 inhibitors have been described. Case report: Herein, we report the case of a 53‐year‐old Caucasian man who obtained complete skin clearance of psoriasis plaques after 16 weeks of ixekizumab treatment together with the appearance of vitiligo patches localized on the facial area. He had never suffered of vitiligo and his family history excluded vitiligo diagnosis. We also could exclude post inflammatory psoriasis hypopigmentation because of absence of facial involvement at baseline. Our experience suggests that vitiligo might be considered a rare adverse effects of anti‐IL‐17 therapy. [ABSTRACT FROM AUTHOR]

Moreover, teledermatology remains a useful tool to monitor and guide patients in their disease treatment, and other dermatological conditions, such as skin cancer, may also benefit from teledermatology [[8]]. In our opinion, patients undergoing biological treatment for chronic inflammatory skin diseases, such as psoriasis, atopic dermatitis and hidradenitis suppurativa, or with a controlled disease may benefit the most from teledermatology [[7]]. However, according to Borgia et al., teledermatology cannot replace face-to-face visits since the physician-patient relationship is at the basis of therapeutic management. [Extracted from the article]

Particularly, conventional systemic treatments are approved only after 18 years of age while phototherapy is time-consuming showing logistic concerns.3 Biologics represent the only officially approved systemic drugs for moderate-to-severe pediatric psoriasis. We observed a complete skin clearance after only 4 weeks of treatment together with a huge improvement in quality of life and skin symptoms (PASI; 0, BSA 0%, Figure 1C,D); these results were maintained up to the last follow up at 24 weeks of treatment. His failed treatment history was wide: topical agents (0.05% clobetasol propionate), 16 weeks of oral cyclosporine (2.5 mg/kg/day) at the age of 9 years and 24 weeks of nb-UVB therapy when he was 10 years. [Extracted from the article]

Simple Summary: Basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (cSCC) are the commonest types of non-melanoma skin cancer. Surgical excision is the mainstay of treatment for both tumors. However, tumor features and patients' comorbidities may limit the use of these techniques, making the treatment challenging. The introduction of oral therapies targeting a pathogenetic pathway in BCC has revolutionized the therapeutic scenario. However, there are still patients unresponsive or intolerant to these drugs. In this context, cemiplimab has been approved as second-line treatment. As regards SCC, cemiplimab was the first systemic therapy approved. The objective of this manuscript was to investigate the efficacy and safety of cemiplimab for the management of BCC and cSCC. Cemiplimab has a durable and significant effect for the management of BCC and CSCC, with a favorable safety profile. Non-melanoma skin cancer includes several types of cutaneous tumors, with basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (cSCC) as the commonest. Among the available therapeutic options, surgical excision is the mainstay of treatment for both tumors. However, tumor features and patients' comorbidities may limit the use of these techniques, making the treatment challenging. As regards BCC, even if hedgehog inhibitors revolutionized the therapeutic scenario, there are still patients unresponsive or intolerant to these drugs. In this context, cemiplimab has been approved as second-line treatment. As regards SCC, cemiplimab was the first systemic therapy approved. The objective of this manuscript was to investigate the efficacy and safety of cemiplimab for the management of BCC and cSCC. Cemiplimab has a durable and significant effect for the management of BCC and CSCC, with a favorable safety profile. Different specialists including oncologists, radiologists, dermatologists, and surgeons are required to guarantee an integrated approach, leading to the best management of patients. Moreover, the collaboration among specialists will allow them to best manage the TEAEs, reducing the risk of treatment suspension or discontinuation. Certainly, ongoing studies and more and more emerging real-world evidence, will allow us to better characterize the role of cemiplimab for the management of advanced non-melanoma skin cancer. [ABSTRACT FROM AUTHOR]

The incidence of cutaneous melanoma (CM) is increasing. CM is defined as melanoma in situ when limited within the epidermis and invasive when atypical melanocytes progressively invade the dermis. Treatment of CM is challenging. On one hand, melanoma in situ does not require further treatment except for a limited secondary excision with reduced margins to minimize the risk of local recurrences; on the other, invasive melanoma requires a personalized approach based on tumor staging. Consequently, an association of surgical and medical treatments is often necessary for invasive forms of the disease. In this scenario, new knowledge on melanoma pathogenesis has led to the development of safe and effective treatments, and several drugs are currently under investigation. However, extensive knowledge is required to offer patients a tailored-tail approach. The aim of our article was to review current literature to provide an overview of treatment options for invasive melanoma, highlighting strategical approaches that can be used in patients with these forms of disease. [ABSTRACT FROM AUTHOR]

Introduction: Basal cell carcinoma (BCC) is the most common skin malignancy in Caucasians. Globally, about 20% of BCCs involve the periocular region. The treatment of periocular BCC may be very challenging because of its proximity to the intracranial structures. Thus, early diagnosis and early treatment is mandatory. Recently, the introduction of Hedgehog pathway inhibitor therapy revolutionized the management of unresectable BCCs. The aim of our study was to evaluate the outcome of sonidegib treatment in patients affected by periocular locally advanced (la) BCC at our skin cancer center. Methods: A 3-year retrospective study was carried out enrolling patients with periocular laBCC treated with sonidegib. Therapeutic response was defined as complete remission (CR) in case of complete regression of the tumor, partial remission (PR) in case of tumor regression not achieving complete remission, and stable disease (SD). Results: A total 16 patients (11 men and 5 women; medium age 71.6 ± 11.5 years) with periocular laBCCs undergoing treatment with 200 mg/day of sonidegib were included in our study. Patients included in the study were treated for at least 6 months for a median duration of 9 months. Overall, CR was reported in 9/16 (56.2%) patients, PR was reported in 4/16 patients (25%), and tumor remained stable in 3 patients (18.8%). No cases of disease progression were collected. Fourteen out of 16 patients experienced multiple adverse events (AEs): dysgeusia was reported in 12 (75%) patients, muscle spasms in 13 (81%) patients, and 7 (43.7%) patients presented with alopecia. However, all of the AEs were mild and none required treatment discontinuation. Conclusion: To the best of our knowledge, this is the first study investigating the effectiveness and safety of sonidegib in the management of BCC localized at the periocular region. Even if limited, our study suggests this drug as a valuable and safe option in periocular BCC management. [ABSTRACT FROM AUTHOR]

In a recent meta-analysis, the average estimated recurrences were 5.0% for wide excisions and 26.0% for partial excisions,[3] although radical surgery is associated with a longer recovery time that can influence the therapeutic choice depending on the patients' needing. Surgical procedures are mentioned in almost all international guidelines, nevertheless, patients' compliance could be not always high due to the fear of wide excisions and reconstructive surgeries. Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease affecting ~1% of the population, with a female prevalence.[1] Management of HS may be challenging since the lack of effective treatments. [Extracted from the article]

The Janus kinase (JAK)-signal transducer and activator of transcription (STAT) pathway plays a critical role in orchestrating immune and inflammatory responses, and it is essential for a wide range of cellular processes, including differentiation, cell growth, and apoptosis. Over the years, this pathway has been heavily investigated due to its key role in the pathogeneses of several chronic inflammatory conditions, e.g., psoriasis, atopic dermatitis (AD), and inflammatory bowel diseases (IBDs). Nevertheless, the impact of this pathway on the pathogenesis of inflammatory conditions remains unclear. This review describes the role of the JAK/STAT signaling pathway in the pathogenesis of inflammatory diseases such as psoriasis (Pso), psoriatic arthritis (PsA), AD, and IBD with a focus on ulcerative colitis (UC) and briefly resumes the use of JAK inhibitors in their clinical management. [ABSTRACT FROM AUTHOR]

We conducted a one-year prospective study involving the enrollment of 58 patients with Hidradenitis Suppurativa. Through a retrospective analysis of data on the same patients, with reference to the year prior to the initiation of the anti-TNFα drug adalimumab, we aimed to show how the advent of this biologic therapy changes the number of days of antibiotic therapy, the number of flare-ups per year, and their duration in days, as well as the quality of life and perceived pain of patients. [ABSTRACT FROM AUTHOR]

Our experience in addition to that described by the authors seems to confirm that vitiligo is a rare adverse event due to anti-IL-17[[2], [4]]; nevertheless, the occurrence of de novo vitiligo is not a contraindication to treatment. Demographic and clinical characteristics of patients with both psoriasis and vitiligo in a cohort of vitiligo patients: a cross-sectional study. [Extracted from the article]

Recent epidemiological studies highlighted a possible link between PsO and demyelinating disorders such as MS.[2] Herein, we reported the case of a 40-year-old female who suffered from PsO and MS successfully treated with a combination therapy of secukinumab and fingolimod. Keywords: fingolimod; multiple sclerosis; psoriasis; real-life experience; secukinumab EN fingolimod multiple sclerosis psoriasis real-life experience secukinumab e100 e102 3 02/17/23 20230201 NES 230201 Dear Editor, Psoriasis (PsO) is a chronic inflammatory disease characterized by erythemato-desquamative plaques with systemic involvement (psoriatic arthritis, metabolic syndrome, cardiovascular disorders, Crohn's disease, and depression).[1] Multiple sclerosis (MS) is an auto-immune neurological disease characterized by inflammation, demyelination, gliosis, and neuronal loss. [Extracted from the article]

Background: The most frequent inflammatory skin diseases are psoriasis, atopic dermatitis, hidradenitis suppurativa, and acne. Their management is challenging for dermatologists since their relapsing chronic clinical course is associated with a great impact on quality of life. Nevertheless, the recent introduction of novel therapies, such as biological drugs and small molecules has been changing the history of these diseases. Methods: A systematic review of the scientific literature of case reports, case series, epidemiological studies, reviews, and systematic reviews regarding teledermatology and inflammatory skin disease. Studies were identified, screened, and extracted for relevant data following the PRISMA (preferred reporting items for systematic reviews and meta-analyses) guidelines. Results: A total of 69 cases articles were included in the review. Conclusions: As we have shown in the review, several experiences of teledermatology for patients affected by inflammatory skin diseases have been demonstrated to increase due to clinical access to hospital and specialized health care services, allowing better access to specialized dermatology care for people living in remote areas, and saving costs and money with health care. [ABSTRACT FROM AUTHOR]

We retrospectively investigated all the surgical excisions with a histopathological diagnosis of melanoma performed in our department from January 2018 to December 2021 in order to analyse how COVID-19 pandemic impacted on melanoma diagnosis during these years. 2022; 36: e762 - 4. https://doi.org/10.1111/jdv.18337 5 Villani A, Fabbrocini G, Scalvenzi M. The reduction in the detection of melanoma during the coronavirus disease 2019 (COVID-19) pandemic in a melanoma center of South Italy. Melanoma is the main cause of death from skin cancer.[1]Its stage at the moment of the diagnosis, particularly primary tumour thickness, is the main prognostic factor, leading to the need for an early diagnosis and treatment.[1] Restrictive measures adopted during COVID-19 pandemic in order to avoid infection spreading led to a reduction in the number of accesses in dermatologic clinics.[[2]] We read with great interest the article recently written by Balakirski et al.[4] evaluating the long-term effect of COVID-19 pandemic on the detection and dermatosurgical treatment of melanoma, and we also want to report the experience of our third-level centre for 'Melanoma Diagnosis and Prevention. [Extracted from the article]

Reply to "A case of symmetrical drug-related intertriginous and flexural exanthema-like eruption associated with Pfizer COVID-19 vaccination" by Manaa et al Dear Editor, We have read with great interest the article recently published by Manaa et al. who reported a case of symmetrical drug-related intertriginous and flexural exanthema (SDRIFE) - like eruption associated with COVID-19 vaccination.[1] We herein describe an analogous case that was referred at the Dermatology Unit of the University Hospital of Naples Federico II, in May 2022. 2021; 35 (10): e634 - e635. doi: 10.1111/jdv.17454 7 Lim PN, Wylie G. Symmetrical drug-related intertriginous and flexural exanthema like eruption associated with COVID-19 vaccination. [Extracted from the article]

Atopic dermatitis (AD) and chronic rhinosinusitis with nasal polyps (CRSwNP) are type-2 inflammatory diseases sharing interleukin (IL)-4 and IL-13 as key mediators.1 However, AD globally affects 15%-20% of children and 5%-10% of adolescents in European countries,2 while CRSwNP is rare with an estimated incidence of 0.21% in patients aged 10-19 years.3 Dupilumab is a monoclonal antibody blocking the -subunit of the IL-4 receptor, shared by IL-4 and IL-13.4,5 It has been shown to be effective and safe in type-2 inflammatory diseases.4,5 Dupilumab is approved in Italy for the treatment of patients with moderate-to-severe AD (>=6 years), severe asthma (>=12 years), or severe CRSwNP (>=18 years).6 A 12-year-old female suffering from AD since the first months of life was first referred to us for the recent worsening of the disease. Since the patient was affected by severe AD, dupilumab 400 mg loading dose and then 200 mg subcutaneously every other week (patient weight: 52 kg) was prescribed. PATIENT CONSENT The authors have obtained the consent of the patient for clinical images. [Extracted from the article]